Literature DB >> 14296025

THALIDOMIDE (N-PHTHALOYLGLUTAMIMIDE) IN THE TREATMENT OF ADVANCED CANCER.

K B OLSON, T C HALL, J HORTON, C L KHUNG, H F HOSLEY.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS; DERMATITIS; DRUG THERAPY; GERIATRICS; LEUKOPENIA; NAUSEA; NEURITIS; PALLIATIVE TREATMENT; PARESTHESIA; THALIDOMIDE; THROMBOPENIA; TOXICOLOGIC REPORT

Mesh：

Substances：

Year:  1965        PMID： 14296025     DOI： 10.1002/cpt196563292

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  15 in total

1.  Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide-dexamethasone.

Authors:  Francesca Magalini; Adriano Stella; Paolo Sansoni
Journal:  Intern Emerg Med       Date:  2008-03-05       Impact factor: 3.397

Review 2.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

3.  New roles for thalidomide.

Authors:  R J Powell
Journal:  BMJ       Date:  1996-08-17

4.  [Experimental studies with cyclic imides in dimethylbenzanthracene tumors of Sprague-Dawley rats].

Authors:  H Mückter; E Frankus; E Moré; W E Kollmer; M Staemmler
Journal:  Z Krebsforsch       Date:  1967

Review 5.  The clinical experience with antiangiogenic agents.

Authors:  J L Marshall; M J Hawkins
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 6.  Potential novel uses of thalidomide: focus on palliative care.

Authors:  V Peuckmann; M Fisch; E Bruera
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 7.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.

Authors:  Lissandra Dal Lago; Marc F Richter; Anna I Cancela; Sabrina A Fernandes; Keylla T Jung; Ana C Rodrigues; Teresa Dalla Costa; Luciane P Di Leone; Gilberto Schwartsmann
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 9.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

10.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.